Intensive Blood Pressure Management Preserves Functional Connectivity in Patients with Hypertension from the Systolic Blood Pressure Intervention Randomized Trial

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIG 1.
Flow diagram for SPRINT participants undergoing fMRI.
Download figure
Open in new tab
Download powerpoint
FIG 2.
Voxelwise t test comparing the longitudinal change of the ASLN between treatment groups. Comparison t map on the right (red box) demonstrates regions of significantly more negative change with time in the standard group compared with the intensive group in the cingulate region and right posterior insula and temporal lobe. Clusters are significant to P < .0001 family-wise error–corrected. BL indicates baseline; FU, Follow-up.

Table 1:

Characteristics of study cohort at baseline^{^a}

	Standard Treatment Group (n = 180)	Intensive Treatment Group (n = 226)
Follow-up period (median) (yr)	3.86	3.82
Age (yr)	67.5 (SD, 8.4)	68.4 (SD, 8.4)
Female sex (No.) (%)	60 (33.3%)	89 (39.4%)
Race (No.) (%)
White	117 (65.0%)	156 (69.0%)
Black	51 (28.3%)	59 (26.1%)
Hispanic	9 (5.0%)	7 (3.1%)
Other	3 (1.7%)	4 (1.8%)
SBP (mm Hg)	139.6 (SD, 18.4)	136.2 (SD, 18.2)
DBP (mm Hg)	82.2 (SD, 13.2)	80.2 (SD, 11.2)
eGFR (mL/min/1.73 m²)	69.1 (SD, 21.3)	65.2 (SD, 19.0)
Serum creatinine level (mg/dL)	1.1 (SD, 0.4)	1.1 (SD, 0.4)
Chronic kidney disease (eGFR <60 mL/min/1.73 m²) (No.) (%)	61 (33.9)	88 (38.9)
Framingham 10-year cardiovascular disease risk score (%)	24.3 (SD, 12.4)	23.5 (SD, 12.6)
TBV (cm³)	1150.9 (SD, 117.0)	1139.3 (SD, 117.3)
rTBV/ICV)	0.82 (SD, 0.04)	0.82 (SD, 0.04)
White matter lesion volume (median) (IQR) (cm³)	1.6 (0.9–3.8)	1.4 (0.6–3.6)

Note:—DBP indicates diastolic blood pressure; IQR, interquartile range; eGFR, estimated glomerular rate; ICV, intracranial volume.
↵a All values provided as means unless otherwise specified.

Table 2:

Subgroup comparisons between treatment groups in longitudinal ΔMCS